Background
HCV infection is common and associated with significant morbidity and mortality among heamodialysis (HD) patients [1]. Heamodialysis is a trusted intermediate procedure for management of chronic kidney disease (CKD) patients. As such CKD is an immune-deficient state, hence blood borne viral infection particularly HCV pose great risk to patients treated by heamodialysis [2]. A high prevalence of HCV infection in heamodialysis patients has been reported in heamodialysis units since the introduction of heamodialysis therapy. Risk factors such as the number of blood transfusions or duration on heamodialysis. The prevalence of HCV infection in patients undergoing dialysis is greater than that in the general population, suggesting that patients on dialysis may be at higher risk of acquiring HCV infection [3].

The cause for the elevated prevalence of HCV infection in heamodialysis patients may be due to the excessive number of transfusions that these patients are frequently submitted to [4] and since the prevalence increases with the duration of dialysis treatment, there is an indication that the environment itself functions as a vehicle in the dissemination of the virus among the patients in dialysis centers [5].

Morales, et al. [6] in a study concerning the prevalence and incidence of infection by HCV in heamodialysis, observed that 70% of the positive patients for anti-HCV had undergone blood transfusion. Sayiner, et al. [7] carried out a study in Turkey that compared patients in heamodialysis with those on CAPD treatment. They observed 6.8% anti-HCV prevalence in CAPD patients, while the heamodialysis patients had a prevalence of 45.7%. The duration of dialysis, the number of transfusions, as well as the number of units of blood received, was the principal factors contributing to the elevated prevalence among heamodialysis patients. In another study conducted in Khartoum, Sudan (2012), showed the prevalence of anti-HCV seropositivity was 8.5% [8] which is low compared with that reported from heamodialysis centers in Sudan (23.7%).
However, the prevalence of HCV varies widely from country to country and also from center to center, even within the same country. This can be attributed to variations in the implementation of infection control measures in these hemodialysis units [10].

There is a scarce of information about HCV in Tanzania, and no published data on the seroprevalence of HCV among hemodialysis patients. Thus the magnitude of HCV transmission within hemodialysis units is still unclear and therefore general recommendations for prevention have not been developed. Therefore this study aimed to determine the prevalence of HCV infection among patients undertaking HD treatments at Muhimbili National Hospital, in Tanzania.

Materials and Methods

Study sample and data collection

120 patients were randomly selected from Muhimbili National Hospital. All patients were interviewed for demographic data and risk factors to HCV infections including history of number of blood transfusion and surgical interventions.

Antibodies screening

All the subjects were screened for anti HCV antibodies third generation test according to the manufacturer instructions (The SD BIO-LINE HCV TEST).

Statistical analysis

Chi-square test were used to accesses the association between HCV positivity and variables. Statistical significance was evaluated at 0.05 levels.

Result

A total of 120 patients were recruited from May to July, 2016. Among of these 101 (84.2%) were males and 19 (15.8%) were females. The overall average age was 51.6 (SD 1.2) years and ranged from 22 to 87 years. Majority of the study participant were in the age group of 55-64, constituting 34 (28.3%). Majority of patients had chronic renal failure 111 (92.5%) while 9 (7.5) had acute renal failure. Out of 120 patients, 4 tested positive for HCV, giving a sero-prevalence of 3.3%. Among 101 (100%) males, 3 (2.9%) were tested positive for HCV whereas 1 (5.3%) female out of 19 (100%) tested positive. The difference is not statistically significance (Chi-square=0.26; p-value=0.61). There was no association of anti-HCV seroprevalence between age groups and education level with p-value of 0.66 and 0.11 respectively. 24 (20%) patients had history of blood transfusion while 27 (22.5%) had history of surgery. The results also show that there is slightly association of blood transfusion and anti-HCV positive results with Chi-square= 7.76; p-value=0.06, while there is no statistical significance for history of surgery and HCV infection (Chi-square=1.78; p-value=0.18) (Figure 1) (Table 1-3).

Table 1: Sero-prevalence of HCV among study participants 4 (3.3%) patients out of 120, were tested positive for anti-HCV.

| SD BioLine Ant-HCV Test Results | Frequency | Percent (%) |
|--------------------------------|-----------|-------------|
| Positive                      | 4         | 3.3         |
| Negative                      | 116       | 96.7        |
| Total                          | 120       | 100         |

Table 2: Sero-prevalence of HCV in relation to socio-demographic characteristics of the study participants.

| Variable | SD BioLine Anti-HCV Test Results | Total |
|----------|---------------------------------|-------|
|          | Positive                        | Negative | Sex of Participants |
| Male     | 3 (2.9%)                        | 98 (97.1%) | 101 (100.0%) |
| Female   | 1 (5.3%)                        | 18 (94.7%) | 19 (100.0%) |
| Age Group|                                 |         | |
| < 25     | 0 (0.0%)                        | 2 (100.0%) | 2 (100.0%) |
| 25 – 34  | 0 (0.0%)                        | 12 (100.0%) | 12 (100.0%) |
| 35 – 44  | 0 (0.0%)                        | 24 (100.0%) | 24 (100.0%) |
| 45 – 54  | 1 (3.6%)                        | 27 (96.4%) | 28 (100.0%) |
| 55 – 64  | 2 (5.9%)                        | 32 (94.1%) | 34 (100.0%) |
| >64      | 1 (5.0%)                        | 19 (95.0%) | 20 (100.0%) |
| Total    | 4                               | 116      | 120           |

Table 3: Risk factors for HCV infection among study participants.

| Variable | Frequency | Anti-HCV Positive |
|----------|-----------|-------------------|
|          |           | Previous Blood Transfusion |
| Yes      | 24        | 3                 |
| No       | 96        | 1                 |
|          |           | History of Surgery |
| Yes      | 27        | 2                 |
| No       | 93        | 2                 |
| Total    | 120       | 4                 |

Figure 1: Type of Renal Failure.
Discussion

HCV infection has a negative impact on the survival of haemodialysis patients, attributed mostly to HCV-related liver disease and its complications. There is also concern about some adverse outcomes after kidney transplantation in HCV-infected patients. Reduced long term patient and graft survival have been observed in HCV-infected kidney recipients. This is the first study to investigate the seroprevalence among renal failure patients before starting haemodialysis treatment at MNH. The seroprevalence (3.3%) was low compared with the study which was done in northwest of Tanzania in the general population; the prevalence of HCV was reported to be 18.8% [5,10] and in other African countries also, for example, 8% in Kenya and 4.5% in Sudan [4,3] strict adherence to universal infection control procedures, combined with other preventative measures and regular screening of patients and staff might explain the low seroprevalence of HCV. Males were more prominent in this study (84.2%) as compared to females, and HCV prevalence sex ratio was 3:1 for males and females. This is consistent with other study conducted [4,2] indicating that the overall seroprevalence among males and females was 66.7% versus 33.3%, respectively and males comprised a greater proportion (67.8%) of all the study participants. There is a significant decrease in GFR with age among men but not among women and therefore the incidence of ESRD seems to be higher in men than women [54], this explains the reason of more men with renal failure than women. The illiterate and age group of 55-64 years were found with the highest prevalence of HCV infection (8.3% and 5.9%, respectively); but, age and education level were not associated with HCV infection in this study. Similar findings were reported in Sudan [4,3] where by illiterate had prevalence of 36.7% and 18.5% was for age group of 50-60 years.

There is high probability that history of surgery and blood transfusion would be the main risk factors for HCV acquisition among renal failure and haemodialysis patients [5,2]. However, in agreement with other studies done [3-6] there was no association between history of surgery and blood transfusion with HCV infection. It is concluded that results in this study suggest that HCV infection have low prevalence (3.3%) among renal failure patients before starting haemodialysis treatment at MNH. History of surgery and blood transfusion showed no association with HCV seropositivity but they are major factors to decrease the prevalence and further prevent new infection from these patients.

Acknowledgement

The authors would like to gratefully acknowledge the kind assistance from Professor Maselle SY (Major supervisor during proposal development) and Dr Majigo M (Head, Department of Microbiology and Immunology at MUHAS) for their help, support, suggestions, encouragement and devotion to this study and their advice and contribution on drafting this work. We would also like to express our sincere thanks to Ms Mashurano M, Mr Zakaria and all staffs and members, Department of Microbiology and Immunology at muhas, for their support during data collection.

References

1. Svetlozar N (2015) Hepatitis C virus infection in patients on maintenance dialysis. Wolters Kluwer Health Clinical Solution 23(7): 24-25.
2. Pradip B, Kalyan D (2012) Prevalence of Hepatitis B and C among Haemodialysis patients of Tripura, India. BJHG 2(1): 10-13.
3. Zamani F, Ameli M, Razmjou S, Shakeri R, Amiri A, et al. (2010) Incidence of hepatitis C infection in patients on haemodialysis: a multicenter study of northern part of Iran. Saudi J Kidney Dis Transpl 21(6): 1169-1171.
4. Mallick NP, Gokal R (1999) Haemodialysis. Lancet 353: 737-742.
5. Allander T, Medin C, Jacobson SH (1994) Hepatitis C transmission in a hemodialysis unit: molecular evidence for spread of virus among patients not sharing equipment. J Med Virol 43(4): 415-419.
6. Morales MF, Lossi JS, Alderete TN, Noli D (1996) Prevalence and seroconversion to HCV in hemodialyzed patients, and epidemiological factors. Transpl Proc 28(6): 3402-3405.
7. Sayiner AA, Zeytinoğlu A, Özkahya M (1999) HCV infection in haemodialysis and CAPD patients. Nephrol Dial Transplant 14(1): 256-257.
8. Dahaba M, Gueye S, Ka E (2014) Trends in hepatitis C infection among haemodialysis patients in Senegal: results of a decade of prevention. Saudi J Kidney Dis Transpl 25(6): 1341-1345.
9. Wann AA, Christopher WM, Maarten WT (2012) Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infect Dis 12: 265.
10. El Amin HH, Osman EM, Mkki MO, Abdelraheem MB, Ismail MO, et al. (2007) Hepatitis C virus infection in haemodialysis patients in Sudan: Two centers’ report. Saudi J Kidney Dis Transplant 18(1): 101-106.